107 related articles for article (PubMed ID: 1625477)
1. Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia.
Browman GP; Preisler HD
Leuk Res; 1992; 16(5):511-9. PubMed ID: 1625477
[TBL] [Abstract][Full Text] [Related]
2. [Bone marrow changes in acute non-lymphocytic leukemia patients treated with low-dose Ara-C--implications of therapeutic mechanism].
Lin SF; Liu HW; Chen JR; Chien CH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Sep; 3(9):612-7. PubMed ID: 3483023
[No Abstract] [Full Text] [Related]
3. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
[TBL] [Abstract][Full Text] [Related]
4. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
Zeremski V; Savić A
Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
[TBL] [Abstract][Full Text] [Related]
5. Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Armstrong SG; Browman GP; Benger AM; Meyer RM; McKay KL; Singh G
Leuk Res; 1994 Sep; 18(9):659-64. PubMed ID: 7934140
[TBL] [Abstract][Full Text] [Related]
6. Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy.
Preisler HD; Raza A; Azarnia N; Rakowsky I; Barcos M; Browman G; Booker L; Goldberg J; Gottleib A; Brennan J
Eur J Cancer Clin Oncol; 1985 May; 21(5):563-71. PubMed ID: 3859416
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside in the initial treatment of acute leukemia.
Barnett MJ; Waxman JH; Richards MA; Ganesan TS; Bragman KS; Rohatiner AZ; Lister TA
Semin Oncol; 1985 Jun; 12(2 Suppl 3):133-8. PubMed ID: 3859927
[No Abstract] [Full Text] [Related]
8. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Roberts MM; Juttner CA; To LB; Kimber RJ
Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
[TBL] [Abstract][Full Text] [Related]
9. Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Balaban EP; Cox JV; Schneider NR; Harth CA; Haley BB; Sheehan R; Frenkel EP
Am J Hematol; 1988 Oct; 29(2):79-84. PubMed ID: 3189306
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response of acute non-lymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Peters WG; Willemze R; Colly LP; Colla L
Br J Haematol; 1985 Apr; 59(4):733-4. PubMed ID: 3857074
[No Abstract] [Full Text] [Related]
11. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
[No Abstract] [Full Text] [Related]
12. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Powell BL; Kute TE; Craig JB; Lyerly ES; Gregory BW; Do KA; Contento MM; Capizzi RL
Leukemia; 1990 May; 4(5):316-20. PubMed ID: 2388477
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of bone-marrow biopsy during induction therapy for acute myeloid leukemia.
Shamdas GJ; Garewal HS; Roe DJ
Lancet; 1992 Jan; 339(8786):178. PubMed ID: 1346026
[No Abstract] [Full Text] [Related]
15. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
16. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y
Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198
[TBL] [Abstract][Full Text] [Related]
17. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside.
Büchner T; Barlogie B; Asseburg U; Hiddemann W; Kamanabroo D; Göhde W
Blut; 1974 Apr; 28(4):299-300. PubMed ID: 4524531
[No Abstract] [Full Text] [Related]
19. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.
Recent Results Cancer Res; 1973; 43():165-8. PubMed ID: 4531077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
